| 常用口服降糖药的药物基因组学研究进展 |
| |
| 引用本文： | 刘谋泽.常用口服降糖药的药物基因组学研究进展[J].微生物学杂志,2017(2). |
| |
| 作者姓名： | 刘谋泽 |
| |
| 作者单位： | 1. 中南大学湘雅医院临床药理研究所,湖南 长沙 410008;2. 中南大学临床药理研究所遗传药理学湖南省重点实验室,湖南 长沙 410078;3. 中
南大学湘雅二医院药学部,湖南 长沙 410011 |
| |
| 基金项目： | 国家重点研究发展计划(No. 2016YFC0905000);国家高
技术研究发展计划“863”项目(No. 2012AA02A518);国家自然科学
基金(No. 81522048,No. 81573511,No. 81273595);中南大学创新
驱动项目(No. 2016CX024) |
| |
| 摘 要： | 近年来,中国 2 型糖尿病(T2DM)发病率呈快速增长趋势。T2DM 是一种慢性代谢性疾病,涉及全身各个系统,甚至可能引起严 重的并发症。大多数 T2DM 患者需长期口服降糖药物。口服降糖药的药物基因组学研究可指导个体化治疗,改善疗效,降低用药成本,减 少不良反应和并发症风险,已成为当前研究的热点。综述常用口服降糖药药效学和药代动力学参数的相关基因多态性研究进展,为更加合理、 有效地进行糖尿病临床个体化治疗提供参考。
|
| 关 键 词： | 2 型糖尿病 口服降糖药 药物基因组 精准医疗 |
Research Progress in Pharmacogenomics of Major Oral Antidiabetic Agents |
| |
| LIU Mouze.Research Progress in Pharmacogenomics of Major Oral Antidiabetic Agents[J].Journal of Microbiology,2017(2). |
| |
| Authors: | LIU Mouze |
| |
| Institution: | In recent years, the incidence of type 2 diabetes (T2DM) in China increased rapidly. T2DM is a chronic metabolic disease involving many organ systems, and may cause serious complications. Most T2DM patients need long-term therapy with oral hypoglycemic drugs. Study on the pharmacogenomics of oral hypoglycemic agents, a hotspot in current research, can guide individualized therapy, improve drug ef cacy, lower treatment cost and reduce the risk of adverse reactions and complications. This paper reviewed the research advances in polymorphisms of genes involved in pharmacokinetics and pharmacodynamics pathways of commonly used oral hypoglycemic agents, providing references for more rational and effective individualized treatment of diabetes. |
| |
| Abstract: | In recent years, the incidence of type 2 diabetes (T2DM) in China increased rapidly. T2DM is a chronic metabolic disease involving many organ systems, and may cause serious complications. Most T2DM patients need long-term therapy with oral hypoglycemic drugs. Study on the pharmacogenomics of oral hypoglycemic agents, a hotspot in current research, can guide individualized therapy, improve drug ef cacy, lower treatment cost and reduce the risk of adverse reactions and complications. This paper reviewed the research advances in polymorphisms of genes involved in pharmacokinetics and pharmacodynamics pathways of commonly used oral hypoglycemic agents, providing references for more rational and effective individualized treatment of diabetes. |
| |
| Keywords: | T2DM oral antidiabetic agents pharmacogenomics precision medicine |
|
| 点击此处可从《微生物学杂志》浏览原始摘要信息 |
| 点击此处可从《微生物学杂志》下载免费的PDF全文 |
|
